The Swiss pharma giant plans to offload its generics unit on or around October 4, it said on Friday. Shareholders will receive one Sandoz share for every five Novartis shares held.
This content was published on
2 minutes
Reuters/sp
Português
pt
Novartis pretende realizar em outubro a cisão da unidade Sandoz
Novartis shareholders will vote on the details of the plan at an extraordinary general meeting (EGM) on September 15, a year after the Basel-based firm announced its plans to split Sandoz into a separate entity, ReutersExternal link and other media reported on Friday.
“If Novartis shareholders approve the proposed special distribution at the EGM, the spin-off will be implemented through the distribution of a dividend-in-kind of Sandoz shares to Novartis shareholders, and of Sandoz ADRs (American Depositary Receipts) to Novartis ADR holders,” the company said in a statement.
The Swiss drugmaker’s plan to separate out its generic drug unit Sandoz is aimed at focusing on the production of more lucrative patent medicines. In 2021, following mounting pricing pressures in the US off-patent medicines sector, Sandoz was put under a strategic review by Novartis CEO Vas Narasimhan.
The generics unit accounted for around 10% of Novartis’ core operating profit of $16.7 billion (CHF14.6 billion) in 2022 and the drug company is now planning to divest almost one-fifth of its business in terms of sales.
Swiss government to improve disaster alert system via mobile phones
This content was published on
The Federal Council wants to modernise the disaster warning system for the population with alerts sent via the mobile phone network and other digital channels.
Poll: most Swiss believe littering is steadily decreasing
This content was published on
Littering is steadily decreasing in Switzerland, according to an annual survey conducted by the Swiss Center of Excellence against Littering.
This content was published on
The Federal Criminal Court has acquitted UBS following appeal proceedings in connection with money laundering charges linked to the Bulgarian mafia. The bank inherited the case from Credit Suisse.
This content was published on
The Swiss Federal Railways (SBB/CFF) timetable change on December 15 will bring improvements for commuters. It will also have new night-time connections on long-distance and regional services.
Swiss launch healthcare initiative to improve working conditions of doctors and nurses
This content was published on
The Swiss authorities have launched an initiative to promote healthcare centres and improve working conditions for doctors, nurses and pharmacists.
Morges fatal shooting: police officer acted in self-defence, prosecutors conclude
This content was published on
The police officer who shot dead a black man at Morges train station in western Switzerland in 2021 acted in self-defence, the Office of the Attorney General of canton Vaud have concluded.
This content was published on
Switzerland has welcomed the announcement of a ceasefire deal between Israel and the Iran-backed group Hezbollah in Lebanon.
Gender wage gap is shrinking in Switzerland – slowly
This content was published on
The gender wage gap is narrowing in Switzerland, although it remains sizeable and partly unexplained: in 2022 women earned on average 16.2% less than their male counterparts.
Swiss national among five survivors rescued after tourist yacht sank in Egypt’s Red Sea
This content was published on
Egyptian naval forces rescued five people on Tuesday, including a Swiss citizen, and recovered four bodies, a day after a tourist yacht carrying 44 passengers sank in the Red Sea.
Novartis seals deal to license high-priced cancer drug
This content was published on
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.